{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T07:56:37Z","timestamp":1793519797355,"version":"4.5.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunoglobulin G4\u2013related disease (IgG4-RD) is an immune-mediated disease with many important manifestations in hematopoietic and lymphoid tissue. IgG4 is the least naturally abundant IgG subclass, and the hallmark feature of IgG4-RD is markedly increased IgG4-positive plasma cells (with an IgG4 to IgG ratio &amp;gt;40%) in affected tissue, along with elevated polyclonal serum IgG and IgG4 in most patients. Histological diagnosis is essential, and other key features include storiform fibrosis, lymphoplasmacytic infiltrate, tissue eosinophilia, and obliterative phlebitis. The disease can present with predominantly proliferative features, such as swollen lacrimal and salivary glands, orbital pseudotumor, autoimmune pancreatitis, polyclonal hypergammaglobulinemia (PHGG), eosinophilia, and tubulointerstitial nephritis of the kidneys, or predominantly fibrotic disease, including mediastinal and retroperitoneal fibrosis, sclerosing mesenteritis, and hypertrophic pachymeningitis. This review focuses on 4 key hematological manifestations: PHGG, IgG4-positive plasma cell enriched lymphadenopathy (LAD), eosinophilia, and retroperitoneal fibrosis (RPF). These features are found in 70%, 60%, 40%, and 25% of IgG4-RD patients, respectively, but can also represent key hematological \u201cmimickers\u201d of IgG4-RD, including Castleman disease (PHGG, LAD), eosinophilic vasculitis (eosinophilia, PHGG, LAD), hypereosinophilic syndromes (eosinophilia, LAD, PHGG), and histiocyte disorders (PHGG, LAD, RPF). An organized approach to these 4 manifestations, and how to distinguish IgG4-RD from its mimickers, is explained. Proliferative manifestations typically respond very well to treatment corticosteroids, rituximab, and other immunosuppressives, whereas chronic fibrotic disease may not be reversible with current treatment modalities.<\/jats:p>","DOI":"10.1182\/hematology.2024000584","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T10:05:25Z","timestamp":1733479525000},"page":"594-603","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["IgG4-related disease for the hematologist"],"prefix":"10.1182","volume":"2024","author":[{"given":"Luke Y. C.","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Hematology, University of British Columbia, Vancouver, British Columbia, Canada; and Division of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"3","key":"2024121115465106000_hem2024000584C1","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3324\/haematol.2018.205526","article-title":"IgG4-related disease: what a hematologist needs to know","volume":"104","author":"Chen","year":"2019","journal-title":"Haematologica"},{"key":"2024121115465106000_hem2024000584C2","doi-asserted-by":"crossref","first-page":"m1067","DOI":"10.1136\/bmj.m1067","article-title":"Advances in the diagnosis and management of IgG4 related disease","volume":"369","author":"Lanzillotta","year":"2020","journal-title":"BMJ"},{"key":"2024121115465106000_hem2024000584C3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev-med-050219-034449","article-title":"Clinical perspectives on IgG4-related disease and its classification","volume":"73","author":"Katz","year":"2022","journal-title":"Annu Rev Med"},{"issue":"10","key":"2024121115465106000_hem2024000584C4","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1056\/NEJM200103083441005","article-title":"High serum IgG4 concentrations in patients with sclerosing pancreatitis","volume":"344","author":"Hamano","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"2024121115465106000_hem2024000584C5","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00535-003-1175-y","article-title":"A new clinicopathological entity of IgG4-related autoimmune disease","volume":"38","author":"Kamisawa","year":"2003","journal-title":"J Gastroenterol"},{"issue":"10","key":"2024121115465106000_hem2024000584C6","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/art.34593","article-title":"Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations","volume":"64","author":"Stone","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2024121115465106000_hem2024000584C7","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"2024121115465106000_hem2024000584C8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.semdp.2012.07.001","article-title":"Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity","volume":"29","author":"Cheuk","year":"2012","journal-title":"Semin Diagn Pathol"},{"issue":"7","key":"2024121115465106000_hem2024000584C9","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/ard-2023-223950","article-title":"Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults","volume":"82","author":"Wallace","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2024121115465106000_hem2024000584C10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjms.2017.08.014","article-title":"Utility of serum IgG4 levels in a multiethnic population","volume":"355","author":"Qi","year":"2018","journal-title":"Am J Med Sci"},{"issue":"2","key":"2024121115465106000_hem2024000584C11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.anai.2020.03.018","article-title":"Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race","volume":"125","author":"Harkness","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3642","key":"2024121115465106000_hem2024000584C12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.146.3642.400","article-title":"Subclasses of human gamma-2-globulin based on differences in the heavy polypeptide chains","volume":"146","author":"Terry","year":"1964","journal-title":"Science"},{"issue":"1","key":"2024121115465106000_hem2024000584C13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/16078454.2020.1815130","article-title":"IgG4 plasma cell myeloma without clinical evidence of IgG4-related disease: a report of two cases","volume":"25","author":"Gauiran","year":"2020","journal-title":"Hematology"},{"key":"2024121115465106000_hem2024000584C14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cca.2020.04.001","article-title":"Clinical utility of serum IgG4 measurement","volume":"506","author":"Varghese","year":"2020","journal-title":"Clin Chim Acta"},{"key":"2024121115465106000_hem2024000584C15","doi-asserted-by":"crossref","first-page":"787422","DOI":"10.3389\/fimmu.2021.787422","article-title":"The role of IgG4 in autoimmunity and rheumatic diseases","volume":"12","author":"Maslinska","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"2024121115465106000_hem2024000584C16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaci.2018.05.011","article-title":"Identification of galectin-3 as an autoantigen in patients with IgG4-related disease","volume":"143","author":"Perugino","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2024121115465106000_hem2024000584C17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/art.41140","article-title":"Disease severity linked to increase in autoantibody diversity in IgG4-related disease","volume":"72","author":"Liu","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2024121115465106000_hem2024000584C18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jaci.2020.05.022","article-title":"CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease","volume":"147","author":"Perugino","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2024121115465106000_hem2024000584C19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/BOR.0000000000000686","article-title":"Immune mechanisms of fibrosis and inflammation in IgG4-related disease","volume":"32","author":"Pillai","year":"2020","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"2024121115465106000_hem2024000584C20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","article-title":"Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts","volume":"78","author":"Wallace","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2024121115465106000_hem2024000584C21","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2665-9913(24)00022-5","article-title":"Proliferative features of IgG4-related disease","volume":"6","author":"Katz","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"2024121115465106000_hem2024000584C22","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2665-9913(23)00299-0","article-title":"Fibrotic phenotype of IgG4-related disease","volume":"6","author":"Lanzillotta","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"2024121115465106000_hem2024000584C23","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol"},{"issue":"1","key":"2024121115465106000_hem2024000584C24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease","volume":"79","author":"Wallace","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2024121115465106000_hem2024000584C25","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1016\/S2352-3026(21)00056-9","article-title":"Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management","volume":"8","author":"Zhao","year":"2021","journal-title":"Lancet Haematol"},{"issue":"3","key":"2024121115465106000_hem2024000584C26","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.3324\/haematol.2019.219725","article-title":"Conditions associated with polyclonal hypergammaglobulinemia in the IgG4-related disease era: a retrospective study from a hematology tertiary care center","volume":"105","author":"Zhao","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"2024121115465106000_hem2024000584C27","doi-asserted-by":"crossref","first-page":"EVIDmr2200035","DOI":"10.1056\/EVIDmr2200035","article-title":"A 54-Year-old woman with cutaneous nodules","volume":"1","author":"Zhao","year":"2022","journal-title":"NEJM Evidence"},{"issue":"1","key":"2024121115465106000_hem2024000584C28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13075-017-1467-x","article-title":"New clues to the nature of immunoglobulin G4-related disease: a retrospective Japanese multicenter study of baseline clinical features of 334 cases","volume":"19","author":"Yamada","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"2024121115465106000_hem2024000584C29","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1093\/rheumatology\/keaa651","article-title":"Differences in clinical characteristics of IgG4- related disease across age groups: a prospective study of 737 patients","volume":"60","author":"Lu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"2024121115465106000_hem2024000584C30","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/art.39205","article-title":"IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients","volume":"67","author":"Wallace","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2024121115465106000_hem2024000584C31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ejh.12059","article-title":"IgG4-related disease with hypergammaglobulinemic hyperviscosity and retinopathy","volume":"90","author":"Wong","year":"2013","journal-title":"Eur J Haematol"},{"issue":"4","key":"2024121115465106000_hem2024000584C32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ccr3.201","article-title":"Polyclonal hyperviscosity syndrome in IgG4-related disease and associated conditions","volume":"3","author":"Chen","year":"2015","journal-title":"Clin Case Rep"},{"issue":"1","key":"2024121115465106000_hem2024000584C33","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1038\/s41598-024-53206-w","article-title":"Mass spectrometry in IgG4-related disease diagnosis","volume":"14","author":"Onwuka","year":"2024","journal-title":"Sci Rep"},{"issue":"34","key":"2024121115465106000_hem2024000584C34","article-title":"Recognizing IgG4-related tubulointerstitial nephritis","volume":"3","author":"Mann","year":"2016","journal-title":"Can J Kidney Health Dis"},{"issue":"2","key":"2024121115465106000_hem2024000584C35","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/PAS.0000000000001579","article-title":"IgG4-related lymphadenopathy: a comparative study of 41 cases reveals distinctive histopathologic features","volume":"45","author":"Bledsoe","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"2024121115465106000_hem2024000584C36","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-23488-0_51","article-title":"Castleman disease","volume-title":"A Clinician's Pearls & Myths in Rheumatology","author":"Chen","year":"2023"},{"issue":"1","key":"2024121115465106000_hem2024000584C37","doi-asserted-by":"crossref","first-page":"e002086","DOI":"10.1136\/rmdopen-2021-002086","article-title":"Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease","volume":"8","author":"Kubo","year":"2022","journal-title":"RMD Open"},{"issue":"1","key":"2024121115465106000_hem2024000584C38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13023-020-01567-6","article-title":"Rosai-Dorfman disease mimicking IgG4- related diseases: a single-center experience in China","volume":"15","author":"Wang","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2024121115465106000_hem2024000584C39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41572-021-00307-9","article-title":"Histiocytic disorders","volume":"7","author":"McClain","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"2024121115465106000_hem2024000584C40","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/his.14428","article-title":"A comparative study of Kimura's disease and IgG4-related disease: similarities, differences and overlapping features","volume":"79","author":"Wang","year":"2021","journal-title":"Histopathology"},{"issue":"5","key":"2024121115465106000_hem2024000584C41","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/bjh.19334","article-title":"Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival","volume":"204","author":"Gao","year":"2024","journal-title":"Br J Haematol"},{"key":"2024121115465106000_hem2024000584C42","article-title":"Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): factors to differentiate from IgG4-related disease [published online 20 February 2024]","author":"Nishikori","journal-title":"J Clin Pathol"},{"issue":"3","key":"2024121115465106000_hem2024000584C43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/ejh.13437","article-title":"Causes of hypereosinophilia in 100 consecutive patients","volume":"105","author":"Moller","year":"2020","journal-title":"Eur J Haematol"},{"issue":"4","key":"2024121115465106000_hem2024000584C44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/ejh.12842","article-title":"IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: a comparative case series","volume":"98","author":"Carruthers","year":"2017","journal-title":"Eur J Haematol"},{"issue":"2","key":"2024121115465106000_hem2024000584C45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MD.0b013e318289610f","article-title":"Rethinking Ormond's disease: \u201cidiopathic\u201d retroperitoneal fibrosis in the era of IgG4-related disease","volume":"92","author":"Khosroshahi","year":"2013","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"2024121115465106000_hem2024000584C46","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/annrheumdis-2020-217408","article-title":"Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging","volume":"79","author":"Schmidkonz","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2024121115465106000_hem2024000584C47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/nrgastro.2016.132","article-title":"IgG4-related hepatobiliary disease: an overview","volume":"13","author":"Culver","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"2024121115465106000_hem2024000584C48","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2024121115465106000_hem2024000584C49","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/ard-2023-224487","article-title":"Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial","volume":"83","author":"Peng","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2024121115465106000_hem2024000584C50","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1016\/S2665-9913(23)00157-1","article-title":"Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial","volume":"5","author":"Perugino","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"suppl 1","key":"2024121115465106000_hem2024000584C51","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1136\/annrheumdis-2021-eular.407","article-title":"AB0756 immune-mediated basis for a phase 2A clinical study comparing rilzabrutinib vs glucocorticoids in rituximab-refractory patients with IGG4-related disease","volume":"80","author":"Long","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2024121115465106000_hem2024000584C52","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2665-9913(21)00359-3","article-title":"Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study","volume":"4","author":"Matza","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"2024121115465106000_hem2024000584C53","doi-asserted-by":"crossref","first-page":"e003026","DOI":"10.1136\/rmdopen-2023-003026","article-title":"IgG4-related disease administered dupilumab: case series and review of the literature","volume":"9","author":"Kanda","year":"2023","journal-title":"RMD Open"},{"key":"2024121115465106000_hem2024000584C54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2024.06.006","article-title":"Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis","volume":"127","author":"Liu","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2024121115465106000_hem2024000584C55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejim.2024.07.028","article-title":"B-cell depletion works in IgG4-related disease. What else?","volume":"127","author":"Della-Torre","year":"2024","journal-title":"Eur J Intern Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/594\/2346808\/594chen.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/594\/2346808\/594chen.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T15:15:17Z","timestamp":1733930117000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/594\/526205\/IgG4-related-disease-for-the-hematologist"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000584","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}